Exelixis Inc is a biopharmaceutical company focused on developing innovative therapies for patients with cancer
The company primarily engages in the discovery, development, and commercialization of small molecule drugs that target key pathways involved in cancer cell growth and survival. Through its research and clinical development programs, Exelixis aims to provide effective treatment options that improve patient outcomes and enhance the quality of life for individuals battling various forms of cancer. The company's commitment to oncology is evident in its robust pipeline of investigational drugs and its ongoing collaborations with other organizations in the healthcare sector.
Exelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL.
Based on a technical and fundamental analysis of NASDAQ:EXEL we conclude: EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
A fundamental and technical analysis of (NASDAQ:EXEL): EXELIXIS INC (NASDAQ:EXEL) may be suited for high growth investing, we'll explore why in this article.
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March:
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, 2025.
NASDAQ:EXEL is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Exelixis, Inc. (Nasdaq: EXEL) today announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC). After more than five years of follow-up, the findings demonstrated that efficacy benefits with CABOMETYX in combination with Opdivo were sustained long term. These results, including subgroup analyses, will be presented at 8:10 a.m. PT on February 15 during Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer at the American Society of Clinical Oncology 2025 Genitourinary Cancers Symposium (ASCO GU).
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the Citi 2025 Virtual Oncology Leadership Summit on Wednesday, February 19 at 2:00 p.m. ET / 11:00 a.m. PT.
Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2024, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
